Le Visage Catherine, Kim Seok Woo, Tateno Kei, Sieber Ann N, Kostuik John P, Leong Kam W
Departments of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.
Spine (Phila Pa 1976). 2006 Aug 15;31(18):2036-42. doi: 10.1097/01.brs.0000231442.05245.87.
To evaluate the in vitro interactions between human mesenchymal stem cells (MSCs) and degenerative disc cells.
To demonstrate the potential of MSCs in regulating the extracellular matrix synthesis of degenerative disc cells.
Culture of degenerative disc cells followed by their reinsertion into a disc can retard the degeneration process in an animal model. However, harvesting cells without accelerating degeneration is problematic. Autologous MSCs can be safely harvested from the bone marrow and transplanted into degenerative discs.
Human degenerative nucleus pulposus (NP), anulus fibrosus (AF) cells, and MSCs were cultured as pellets, and coculture pellets were formed by addition of MSCs to disc cells (50:50 ratio). Glycosaminoglycan (GAG) and DNA content were measured. Proteoglycan synthesis was analyzed by RT-PCR and western blot. Type II collagen expression was assessed by immunohistochemistry.
Coculture pellets formed by the addition of MSCs to AF cells were superior in size to all other pellets. AF/MSC pellets showed higher experimental GAG content than the predicted values represented by the sum of individual control pellets, with 10.2 versus 5.6 microg/pellet at week 3, respectively. The effect was not observed in the NP/MSC coculture, or when chondrogenic medium was used. Close contact between cells was necessary to obtain this enhancement of GAG content. Proteoglycan and collagen expression in both individual and coculture pellets was confirmed by PCR analysis and western blot.
Addition of MSCs to AF cells resulted in an up-regulation of the proteoglycans synthesis. This study provides the rationale for further investigation of the potential of MSC therapy in treating intervertebral disc degeneration.
评估人间充质干细胞(MSCs)与退变椎间盘细胞之间的体外相互作用。
证明MSCs在调节退变椎间盘细胞细胞外基质合成方面的潜力。
培养退变椎间盘细胞然后将其重新植入椎间盘可延缓动物模型中的退变过程。然而,在不加速退变的情况下获取细胞存在问题。自体MSCs可安全地从骨髓中获取并移植到退变椎间盘中。
将人退变髓核(NP)、纤维环(AF)细胞和MSCs培养成小球,通过向椎间盘细胞中添加MSCs(50:50比例)形成共培养小球。测量糖胺聚糖(GAG)和DNA含量。通过逆转录聚合酶链反应(RT-PCR)和蛋白质印迹法分析蛋白聚糖合成。通过免疫组织化学评估II型胶原表达。
向AF细胞中添加MSCs形成的共培养小球在大小上优于所有其他小球。AF/MSC小球在第3周时的实验GAG含量高于单个对照小球总和所代表的预测值,分别为10.2微克/小球对5.6微克/小球。在NP/MSC共培养中或使用软骨形成培养基时未观察到这种效果。细胞之间的紧密接触对于获得GAG含量的这种增加是必要的。通过PCR分析和蛋白质印迹法证实了单个小球和共培养小球中蛋白聚糖和胶原的表达。
向AF细胞中添加MSCs导致蛋白聚糖合成上调。本研究为进一步研究MSC治疗椎间盘退变的潜力提供了理论依据。